Crescent Grove Advisors LLC Has $223,000 Position in Pfizer Inc. (NYSE:PFE)

Crescent Grove Advisors LLC trimmed its holdings in shares of Pfizer Inc. (NYSE:PFE) by 12.9% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 7,719 shares of the biopharmaceutical company’s stock after selling 1,141 shares during the quarter. Crescent Grove Advisors LLC’s holdings in Pfizer were worth $223,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of PFE. China Universal Asset Management Co. Ltd. bought a new stake in shares of Pfizer in the first quarter valued at about $315,000. Central Pacific Bank Trust Division bought a new position in shares of Pfizer during the 1st quarter worth approximately $136,000. GSA Capital Partners LLP bought a new stake in shares of Pfizer in the first quarter worth $439,000. Advisory Alpha LLC boosted its holdings in Pfizer by 2.4% during the first quarter. Advisory Alpha LLC now owns 31,067 shares of the biopharmaceutical company’s stock worth $862,000 after purchasing an additional 737 shares during the last quarter. Finally, CFO4Life Group LLC grew its position in Pfizer by 4.0% in the first quarter. CFO4Life Group LLC now owns 25,703 shares of the biopharmaceutical company’s stock valued at $713,000 after purchasing an additional 985 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Pfizer

In other Pfizer news, Director Scott Gottlieb bought 1,000 shares of Pfizer stock in a transaction dated Wednesday, October 30th. The stock was bought at an average price of $28.24 per share, with a total value of $28,240.00. Following the completion of the transaction, the director now owns 10,000 shares in the company, valued at $282,400. The trade was a 0.00 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 0.06% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the company. Daiwa Capital Markets upgraded Pfizer from a “neutral” rating to an “outperform” rating and raised their price objective for the company from $28.00 to $34.00 in a report on Wednesday, August 7th. Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research note on Wednesday, October 23rd. StockNews.com raised Pfizer from a “hold” rating to a “buy” rating in a research report on Wednesday, October 9th. Evercore ISI raised Pfizer to a “strong-buy” rating in a report on Wednesday, October 30th. Finally, UBS Group boosted their target price on shares of Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a report on Wednesday, July 31st. Eight research analysts have rated the stock with a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, Pfizer presently has a consensus rating of “Moderate Buy” and a consensus target price of $33.58.

Pfizer Stock Performance

NYSE PFE opened at $27.35 on Thursday. The stock has a market cap of $154.98 billion, a PE ratio of 36.96, a P/E/G ratio of 0.88 and a beta of 0.67. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.60 and a current ratio of 0.86. The firm has a 50-day moving average of $28.96 and a 200-day moving average of $28.64. Pfizer Inc. has a 52-week low of $25.20 and a 52-week high of $31.54.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.42. Pfizer had a net margin of 7.07% and a return on equity of 16.40%. The firm had revenue of $17.70 billion during the quarter, compared to the consensus estimate of $14.92 billion. During the same period last year, the business posted ($0.17) earnings per share. The business’s revenue for the quarter was up 31.2% compared to the same quarter last year. On average, sell-side analysts anticipate that Pfizer Inc. will post 2.96 EPS for the current year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be paid a $0.42 dividend. The ex-dividend date of this dividend is Friday, November 8th. This represents a $1.68 annualized dividend and a yield of 6.14%. Pfizer’s dividend payout ratio (DPR) is presently 227.03%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.